These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36153005)

  • 1. Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function.
    Arici M; Ferrandi M; Barassi P; Hsu SC; Torre E; Luraghi A; Ronchi C; Chang GJ; Peri F; Ferrari P; Bianchi G; Rocchetti M; Zaza A
    J Pharmacol Exp Ther; 2023 Jan; 384(1):231-244. PubMed ID: 36153005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective SERCA2a activator as a candidate for chronic heart failure therapy.
    Arici M; Hsu SC; Ferrandi M; Barassi P; Ronchi C; Torre E; Luraghi A; Chang GJ; Ferrari P; Bianchi G; Peri F; Zaza A; Rocchetti M
    J Transl Med; 2024 Jan; 22(1):77. PubMed ID: 38243248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy.
    Torre E; Arici M; Lodrini AM; Ferrandi M; Barassi P; Hsu SC; Chang GJ; Boz E; Sala E; Vagni S; Altomare C; Mostacciuolo G; Bussadori C; Ferrari P; Bianchi G; Rocchetti M
    Cardiovasc Res; 2022 Mar; 118(4):1020-1032. PubMed ID: 33792692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart Failure.
    Luraghi A; Ferrandi M; Barassi P; Arici M; Hsu SC; Torre E; Ronchi C; Romerio A; Chang GJ; Ferrari P; Bianchi G; Zaza A; Rocchetti M; Peri F
    J Med Chem; 2022 May; 65(10):7324-7333. PubMed ID: 35580334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition.
    Ferrandi M; Barassi P; Tadini-Buoninsegni F; Bartolommei G; Molinari I; Tripodi MG; Reina C; Moncelli MR; Bianchi G; Ferrari P
    Br J Pharmacol; 2013 Aug; 169(8):1849-61. PubMed ID: 23763364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure.
    Micheletti R; Palazzo F; Barassi P; Giacalone G; Ferrandi M; Schiavone A; Moro B; Parodi O; Ferrari P; Bianchi G
    Am J Cardiol; 2007 Jan; 99(2A):24A-32A. PubMed ID: 17239701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure.
    Gheorghiade M; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Valentini G; Sabbah HN;
    J Am Coll Cardiol; 2008 Jun; 51(23):2276-85. PubMed ID: 18534276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output.
    Gheorghiade M; Ambrosy AP; Ferrandi M; Ferrari P
    Discov Med; 2011 Aug; 12(63):141-51. PubMed ID: 21878191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial.
    Shah SJ; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Grzybowski J; Valentini G; Sabbah HN; Gheorghiade M;
    Am Heart J; 2009 Jun; 157(6):1035-41. PubMed ID: 19464414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?
    Khan H; Metra M; Blair JE; Vogel M; Harinstein ME; Filippatos GS; Sabbah HN; Porchet H; Valentini G; Gheorghiade M
    Heart Fail Rev; 2009 Dec; 14(4):277-87. PubMed ID: 19238540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular Mechanisms Underlying the Low Cardiotoxicity of Istaroxime.
    Racioppi MF; Burgos JI; Morell M; Gonano LA; Vila Petroff M
    J Am Heart Assoc; 2021 Jul; 10(14):e018833. PubMed ID: 34219467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SERCA2a stimulation by istaroxime: a novel mechanism of action with translational implications.
    Huang CL
    Br J Pharmacol; 2013 Oct; 170(3):486-8. PubMed ID: 23822610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
    Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
    Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting SERCA2a as an innovative approach to the therapy of congestive heart failure.
    Ferrari P; Micheletti R; Valentini G; Bianchi G
    Med Hypotheses; 2007; 68(5):1120-5. PubMed ID: 17113239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of sarcoplasmic reticulum function by PST2744 [istaroxime; (E,Z)-3-((2-aminoethoxy)imino) androstane-6,17-dione hydrochloride)] in a pressure-overload heart failure model.
    Rocchetti M; Alemanni M; Mostacciuolo G; Barassi P; Altomare C; Chisci R; Micheletti R; Ferrari P; Zaza A
    J Pharmacol Exp Ther; 2008 Sep; 326(3):957-65. PubMed ID: 18539651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Istaroxime, a positive inotropic agent devoid of proarrhythmic properties in sensitive chronic atrioventricular block dogs.
    Bossu A; Kostense A; Beekman HDM; Houtman MJC; van der Heyden MAG; Vos MA
    Pharmacol Res; 2018 Jul; 133():132-140. PubMed ID: 29753687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium.
    Wallner M; Khafaga M; Kolesnik E; Vafiadis A; Schwantzer G; Eaton DM; Curcic P; Köstenberger M; Knez I; Rainer PP; Pichler M; Pieske B; Lewinski DV
    Oncotarget; 2017 Jul; 8(30):49264-49274. PubMed ID: 28514771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Istaroxime follow-on compounds: A new class of selective SERCA2a activators for chronic heart failure treatment.
    Arici M; Hsu SC; Ferrandi M; Barassi P; Ronchi C; Torre E; Luraghi A; Metallo A; Chang GJ; Ferrari P; Bianchi G; Regonesi ME; Airoldi C; Peri F; Zaza A; Rocchetti M
    Vascul Pharmacol; 2024 Jun; 155():107295. PubMed ID: 38985597
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of the PLN p.Arg14del Mutation in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Badone B; Ronchi C; Lodola F; Knaust AE; Hansen A; Eschenhagen T; Zaza A
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the New Inotropic Agent Istaroxime in Acute Heart Failure.
    Forzano I; Mone P; Mottola G; Kansakar U; Salemme L; De Luca A; Tesorio T; Varzideh F; Santulli G
    J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36556120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.